Description

Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta

The purpose of the study is to determine whether treatment with Denosumab is safe and effective in children with osteogenesis imperfecta. The study population are children diagnosed with osteogenesis imperfecta who are 2 to 17 years of age. To participate contact please Beverly Feldman at (832) 822-4301 or bfeldman@bcm.edu.

Contact

Beverly Feldman, RN, MSN bfeldman@bcm.eduPhone 1: (832) 822-4301
IRB: h-36030

Status

Active

Created

Jun 23, 2017